馃専 Thanks to @LeXiuning for joining us for a fantastic interview at #ESMO26 today!
鉃★笍 Stay tuned for the interview and more #ESMO2026 news here: https://buff.ly/ELwc5c9
#NSCLC #lcsm
111 views 路 3 likes 路 0 reposts 路 0 replies
Prospective validation of artificial intelligence (AI)鈥揳ssisted RECIST 1.1 in a phase 1 study of fetrastobart vedotin in patients with non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgAI-driven quantification of PD-L1 tumor proportion score (TPS) from immunohistochemistry slides in non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.orgSource: Lung Cancers Today 路 x.com